Trials / Completed
CompletedNCT06106113
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired liver function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GST-HG171 Tablets | 150mg GST-HG171 Tablets |
Timeline
- Start date
- 2022-12-15
- Primary completion
- 2023-02-06
- Completion
- 2023-05-30
- First posted
- 2023-10-30
- Last updated
- 2023-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06106113. Inclusion in this directory is not an endorsement.